 |
|
The Research on Adverse Drug Events and Reports (RADAR) Project
Charles L. Bennett, MD, PhD, MPP;
Jonathan R. Nebeker, MS, MD;
E. Allison Lyons, BA;
Matthew H. Samore, MD;
Marc D. Feldman, MD;
June M. McKoy, MD, JD, MPH;
Kenneth R. Carson, MD;
Steven M. Belknap, MD;
Steven M. Trifilio, RPH;
Glen T. Schumock, PharmD, MBA;
Paul R. Yarnold, PhD;
Charles J. Davidson, MD;
Andrew M. Evens, DO;
Timothy M. Kuzel, MD;
Jorge P. Parada, MD, MPH;
Denis Cournoyer, MD;
Dennis P. West, PhD;
Oliver Sartor, MD;
Martin S. Tallman, MD;
Dennis W. Raisch, PhD
JAMA. 2005;293:2131-2140.
Context In 1998, a multidisciplinary team of investigators initiated RADAR (Research on Adverse Drug events And Reports), a clinically based postmarketing surveillance program that systematically investigates and disseminates information describing serious and previously unrecognized adverse drug and device reactions (ADRs).
Objective To describe the structure, operations, and preliminary findings from the RADAR project and related dissemination efforts by pharmaceutical suppliers and the US Food and Drug Administration (FDA).
Design After identifying a serious and unexpected clinical event suitable for further investigation, RADAR collaborators postulated clinical hypotheses and derived case series and incidence estimates from physician queries, published and unpublished clinical trials, published case reports, FDA databases, and manufacturer sales figures.
Results RADAR investigators identified 16 types of serious ADRs among 1699 patients, of whom 169 (10%) died as a result of the reaction. Initial cases were identified by 7 RADAR investigators, 4 collaborating physicians, 2 attorneys, and by reviewing 3 published reports. Additional sources included queries of occupational health programs and medical directors of interventional cardiology laboratories (3 types of ADRs), published manuscripts and clinical trials (11 types of ADRs), review of medical records at a RADAR site (2 types of ADRs), unpublished clinical trial reports (3 types of ADRs), and reports from attorneys, family members, or patients (4 types of ADRs). Incidence estimates, ranging from 0.4% to 33%, were derived from 5 clinical trial reports, 2 physician queries, and 2 observational databases. Laboratory support for hypotheses included identification of 3 neutralizing antibodies and 3 histopathological findings. ADR reports were disseminated as 8 revised package inserts, 7 "dear doctor" letters, and 9 peer-reviewed articles.
Conclusion A new, clinically based, hypothesis-driven approach to postmarketing surveillance may supplement existing regulatory surveillance systems and improve patient safety.
Author Affiliations: Jesse Brown VA Medical Center/Mid-West Center for Health Services and Policy Research, Chicago, Ill (Drs Bennett and Parada); Divisions of Hematology/Oncology (Ms Lyons, Drs Bennett, Carson, Evens, Kuzel, and Tallman), Division of Cardiology (Dr Davidson), Department of Emergency Medicine (Dr Yarnold), Division of General Internal Medicine (Dr Belknap), Division of Geriatric Medicine (Dr McKoy), Department of Dermatology (Dr West), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Ill (Drs Bennett, Carson, Evens, Kuzel, Tallman); Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Ill (Mr Trifilio); Institute for Health Services Research and Policy Studies at Northwestern University, Evanston, Ill (Drs Carson and Bennett); Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago (Dr Schumock); San Antonio VA and the Department of Medicine at the University of Texas at San Antonio, San Antonio (Dr Feldman); VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, University of New Mexico, Albuquerque (Dr Raisch); University of Utah School of Medicine and the Salt Lake City VA, Salt Lake City (Drs Nebeker and Samore); Departments of Medicine and Oncology, McGill University, Montreal, Canada (Dr Cournoyer); Stanley Scott Cancer Center and the Divisions of Hematology/Oncology of the Louisiana State University School of Medicine, New Orleans (Dr Sartor).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
The RADAR Project and the FDA
Anne E. Trontell
JAMA. 2005;294(10):1206.
EXTRACT
| FULL TEXT
The RADAR Project and the FDA—Reply
Charles L. Bennett, Jonathan R. Nebeker, and Dennis W. Raisch
JAMA. 2005;294(10):1206-1207.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
Chen et al.
J Am Coll Cardiol Intv 2009;2:583-593.
ABSTRACT
| FULL TEXT
Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate
Dorr et al.
Clin. Cancer Res. 2009;15:3850-3855.
ABSTRACT
| FULL TEXT
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Carson et al.
Blood 2009;113:4834-4840.
ABSTRACT
| FULL TEXT
Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study
Zhang et al.
BMJ 2009;338:a2752-a2752.
ABSTRACT
| FULL TEXT
Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR Project
Bennett et al.
J Am Coll Cardiol 2007;50:1138-1143.
ABSTRACT
| FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
Hershman et al.
JNCI J Natl Cancer Inst 2007;99:196-205.
ABSTRACT
| FULL TEXT
Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study.
Page et al.
Arch Intern Med 2006;166:1863-1870.
ABSTRACT
| FULL TEXT
How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation
Reed et al.
Health Aff (Millwood) 2006;25:1309-1317.
ABSTRACT
| FULL TEXT
Reply
Nebeker et al.
J Am Coll Cardiol 2006;48:593-594.
FULL TEXT
A safety assessment tool for formulary candidates.
Pick et al.
Am J Health Syst Pharm 2006;63:1269-1272.
FULL TEXT
Allergic Reactions After the Implantation of Drug-Eluting Stents: Is it the Pill or the Polymer?
Azarbal and Currier
J Am Coll Cardiol 2006;47:182-183.
FULL TEXT
Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents: A Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project
Nebeker et al.
J Am Coll Cardiol 2006;47:175-181.
ABSTRACT
| FULL TEXT
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
Bennett et al.
Blood 2005;106:3343-3347.
ABSTRACT
| FULL TEXT
The RADAR Project and the FDA
Trontell
JAMA 2005;294:1206-1206.
FULL TEXT
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman et al.
Circulation 2005;112:759-770.
FULL TEXT
|
